What is HC Wainwright's Estimate for Korro Bio Q2 Earnings?

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Analysts at HC Wainwright raised their Q2 2025 earnings per share (EPS) estimates for shares of Korro Bio in a note issued to investors on Thursday, May 8th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($2.25) per share for the quarter, up from their prior estimate of ($2.67). HC Wainwright has a "Buy" rating and a $100.00 price objective on the stock. The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share. HC Wainwright also issued estimates for Korro Bio's Q3 2025 earnings at ($1.88) EPS, Q4 2025 earnings at ($1.95) EPS, FY2025 earnings at ($8.57) EPS, Q1 2026 earnings at ($2.00) EPS, Q2 2026 earnings at ($2.05) EPS and Q3 2026 earnings at ($2.11) EPS.

Korro Bio (NASDAQ:KRRO - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($2.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.60) by $0.11. The company had revenue of $2.55 million for the quarter, compared to the consensus estimate of $0.13 million.

A number of other research firms also recently issued reports on KRRO. Cantor Fitzgerald raised Korro Bio to a "strong-buy" rating in a research report on Tuesday, April 29th. Chardan Capital reissued a "buy" rating and set a $25.00 price target on shares of Korro Bio in a research report on Tuesday. Royal Bank of Canada reduced their price target on shares of Korro Bio from $105.00 to $95.00 and set an "outperform" rating for the company in a research report on Wednesday, March 19th. Finally, Oppenheimer dropped their price objective on shares of Korro Bio from $155.00 to $90.00 and set an "outperform" rating on the stock in a research note on Tuesday. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $104.63.

Korro Bio Trading Down 9.3%

NASDAQ:KRRO traded down $1.44 during midday trading on Monday, hitting $14.11. 107,465 shares of the company traded hands, compared to its average volume of 98,182. The firm's fifty day moving average is $17.53 and its 200-day moving average is $33.59. Korro Bio has a 12-month low of $11.13 and a 12-month high of $98.00. The firm has a market capitalization of $132.51 million, a P/E ratio of -1.49 and a beta of 2.66.

Institutional Investors Weigh In On Korro Bio

Hedge funds and other institutional investors have recently bought and sold shares of the business. Alliancebernstein L.P. purchased a new stake in Korro Bio during the 4th quarter worth about $26,870,000. Driehaus Capital Management LLC lifted its position in Korro Bio by 220.3% during the 4th quarter. Driehaus Capital Management LLC now owns 494,905 shares of the company's stock worth $18,841,000 after acquiring an additional 340,410 shares in the last quarter. Woodline Partners LP acquired a new position in Korro Bio during the 4th quarter worth approximately $3,887,000. Franklin Resources Inc. acquired a new position in Korro Bio during the 4th quarter worth approximately $3,493,000. Finally, Aberdeen Group plc acquired a new position in shares of Korro Bio in the 1st quarter valued at approximately $1,470,000. Institutional investors and hedge funds own 13.18% of the company's stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).